Intuitive Surgical: 1 Thing Citron Got Right

By now every Intuitive Surgical (NASDAQ: ISRG  ) investor is aware of "the report." Of course, that's a reference to the well-structured bear thesis laid out by Citron Research last month, clobbering shares of the medical robotics giant in the process.

Today, however, shareholders are marching to the beat of a different drum. After Intuitive far exceeded analyst expectations and issued equally strong guidance, Citron's stance is being rejected.

In this video, Motley Fool health care bureau chief Brenton Flynn takes a closer look at Citron's points in the context of this quarter's Intuitive Surgical earnings report, including one area where he and Citron tend to agree.

If you want exclusive, members-only analysis of Intuitive Surgical, be sure to check out this brand-new premium report. A bearish research report has investors questioning the company's future, and analyst Karl Thiel recently released his exclusive take on the news. As one of the key minds behind our Rule Breakers recommendation of the stock in 2005 (before it went on to gain more than 1,000%), Thiel knows the Intuitive Surgical story inside and out. The report is a must-read for any current or prospective investor, and it comes with a full year of analyst updates. Be sure to claim your copy today by clicking here now.